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C-CBL PHOSPHORYLATION STATUS INFLUENCES COLORECTAL 
CANCER CELL SURVIVAL IN A WNT-DEPENDENT MANNER  
LAWRENCE PRINCE-WRIGHT 
ABSTRACT 
 
 Hyperactive Wnt signaling is the seminal event in colorectal cancer (CRC) 
pathogenesis, where β-catenin serves as a key Wnt mediator enhancing CRC cell 
proliferation and survival.  c-Cbl is a unique E3 ligase, which degrades both mutant and 
active (tumorigenic) β-catenin. c-Cbl phosphorylation at tyrosine 731 (Y731) regulates its 
binding and down regulation of β-catenin specifically in the presence of Wnt ligand 
(Wnt-on state). Since aberrant Wnt signaling activation is found in almost all cases of 
human CRC, it would be critical to understand the influence of c-Cbl phosphorylation on 
CRC cell survival. We hypothesized that c-Cbl phosphorylation regulates CRC cell 
survival in a Wnt dependent manner, a state that is mediated through mutations in β-
catenin or adenomatosis polyposis coli (APC).  
Cbl phosphorylation was examined in a panel of Wnt-off cells with wild-type β-
catenin and APC CRC cell line (RKO cell line) and Wnt-on cell lines with mutant APC 
(Wnt-on- DLD1, HCT15 cell line) or mutant β-catenin (HCT116) using phospho-specific 
antibodies to c-Cbl tyrosine residues at 700 (Y700), 731 and 774 (Y774) positions. 
Biological significance of specific phosphorylation sites was evaluated with phospho-
inactive mutants of c-Cbl (Y700F, Y731F and Y774F) using both the MTT cell 
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proliferation assay and the non-adherent colony formation assay. Potential meditators of 
c-Cbl were examined using immunoblotting.  
Here we show that c-Cbl was phosphorylated at all three major phosphorylation 
sites (Y700, Y731 and Y774) in both Wnt-off and Wnt-on CRC cell lines. However, the 
amount of phosphorylation was reduced in Wnt-on CRC cell lines (DLD1, HCT116 and 
HCT15) compared to Wnt-off (RKO) cell line. Wild-type c-Cbl significantly enhanced 
survival in RKO cell lines and reduced survivability in DLD1 cell lines. In contrast to the 
effect of wild-type c-Cbl, Y731F increased CRC cell survival and non-adherent colony 
forming units. Our preliminary data suggests that c-Cbl Y731 mutation regulates CRC 
survival through β-catenin. c-Cbl is heavily phosphorylated in CRC cell lines, where 
wild-type c-Cbl significantly inhibits cell survival in Wnt-on and enhances cell survival 
in Wnt-off CRC cell lines. Furthermore, our data indicates that Y731 influences CRC 
survival and colony formation only in Wnt-on cell lines. Though further validation is 
required, this dichotomy in the effect of c-Cbl phosphorylation on CRC survival being 
mediated by Wnt status can be further explored as a potentially novel therapeutic target in 
mutant CRC tumors, which represent more than 90% of CRC cases in humans.  
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1. INTRODUCTION  
 
1.1 Prevalence of Colorectal Cancer in the United States 
Despite clinical advances and scientific developments in the molecular basis and 
treatment of colorectal cancer (CRC), it remains the third leading cause of death from 
cancer amongst adults1. Approximately 70,000 cases are diagnosed annually, and 9% of 
all cancer related deaths are attributed to CRC (Figure 1)1.  
 
 
Figure 1| The incidence of cancer through years 1975 to 2009, categorized by type for both sexes.  
Colorectal carcinoma has maintained the 3rd highest prevalence among males for 34 years, and among 
females for 18 years. Figure taken from Siegel, et al. 20132 
 
Lifetime Probability f Developing Cancer
The lifetime p obability of being diagn sed with an
invasive cancer is higher for men (45%) than for women
(38%) (Table 4). However, because of the earlier median
age at diagnosis for breast cancer compared with other
major cancers, women have a slightly higher probability of
developing cancer before age 60 years. These estimates are
based on the average experience of the general population
and may over- or underestimate individual risk because of
differences in exposure (eg, smoking history) and/or genetic
susceptibility.
Trends in Cancer Incidence
Figures 2 to 5 depict long-term trends in cancer incidence
and death rates for all cancers combined and for selected
cancer sites by sex. While incidence rates are declining for
most cancer sites, they are increasing among both men and
women for melanoma of the skin and cancers of the liver
and thyroid (Fig. 3, Table 5). Table 5 shows incidence
(delay-adjusted) and mortality trends for all cancers com-
bined and for selected cancer sites based on joinpoint regres-
sion analysis. Joinpoint is a tool used to describe and quantify
trends by fitting observed rates to lines connected at ‘‘join-
points’’ where trends change in direction or magnitude.13,15
Accordi g to data from the SEER 13 cancer registries, inci-
dence rates in the most recent 5 years (2005-2009) decreased
in males by 0.6% per year and were stable in females (Table
5). Incidence rates are decreasing for all 4 major cancer sites
except female breast, for which rates remained relatively
stable from 2005 to 2009 after decreasing by 2% per year
from 1999 to 2005. Lung cancer incidence rates in women
began declining in the late 1990s, more than a decade after
the decline began in men.6 Differences in lung cancer inci-
dence patterns between men and women reflect historical
differences in tobacco use; cigarette smoking prevalence
peaked about 20 years later in women than in men.16 Recent
rapid declines in colorectal cancer incidence rates have
largely been attributed to increases in screening that can
detect and allow the removal of precancerous polyps.17-19
Although joinpoint trend analysis shows that the incidence
rate for prostate cancer declined steadily by 1.9% per year
from 2000 to 2009, it is important to realize that annual
rates fluctuate widely (Fig. 3), likely reflecting variation in
the prevalence of prostate-specific antigen testing for the
detection of prostate cancer. For example, in the SEER 13
areas, the delay-adjusted prostate cancer incidence rate
increased from 154 (per 100,000) to 164 from 2005 to 2006,
then dropped from 168 to 153 from 2007 to 2008.
FIGURE 3. Trends in Incidence Rates for Selected Cancers by Sex, United States, 1975 to 2009.
Rates are age adjusted to the 2000 US standard population and adjusted for delays in reporting.
*Liver includes intrahepatic bile duct.
VOLUME 63 _ NUMBER 1 _ JANUARY/FEBRUARY 2013 17
CA CANCER J CLIN 2013;63:11–30
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1.2 Wnt/β-catenin Signal Transduction Pathway 
Occurring in every cell, signal transduction pathways are important chain-like 
events that allow for biological signals to target and affect groups of cells 
simultaneously3. A signaling ligand will bind to an extra or intracellular receptor 
initiating a cascade of downstream events with the conclusive goal of targeting gene 
expression4. Recent discoveries in the field of molecular biology have highlighted the 
significance of the highly conserved Wnt/β-catenin signaling pathway5, which  plays  
fundamental roles in the regulation of cell proliferation, migration, angiogenesis6 and 
preservation of cell survival7.  
In most of the cells, β-catenin exists in three distinct compartments with different 
functionalities8. The membrane pool of β-catenin predominates and regulates cell-cell 
junctions9. On the other hand, the cytosolic pool is kept under tight regulation by the 
‘destruction complex’10. The nuclear pool of β-catenin is the final effector pool that 
elicits transcriptional regulation11. Wnt signaling is constitutively suppressed in the 
absence of Wnt ligands12, where the cytosolic β-catenin is kept low. Since cytosolic β-
catenin undergoes free cytosolic-nuclear shuttle, under basal condition, the nuclear β-
catenin is also kept minimal13.  The destruction complex is the primary multi-protein 
complex that regulates cytosolic β-catenin14.  
The main constituents of the β-catenin destruction complex is adenomatous 
polyposis coli (APC), and a scaffolding protein known as axin13. In the presence of 
glycogen synthase kinase-3β (GSK-3β) a single axin helix binds to the hydrophobic 
groove in the C-terminus of GSK-3β13 allowing the biologically active portion of GSK-
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3β to phosphorylate both serine and threonine residues at the N-terminus of β-catenin6. 
Ensuing β-catenin phosphorylation, E3-ligase proteins β-TrCP and Jade-1 explicitly 
recognize phosphorylated β-catenin10,6 targeting it for ubiquitination10 followed by 
proteosomal degradation15. Conversely, in the presence of Wnt ligand β-catenin lacks 
phosphorylation, escapes the degradation complex and translocates to the nucleus, where 
it influences several Wnt target genes6. For example, colonic adenomas with mutations in 
the Wnt signaling pathway have been demonstrated to up-regulate vascular endothelial 
growth factor expression (VEGF)16, consequently promoting both angiogenesis and 
lymphangiogenesis via tyrosine kinase receptors (RTK)17. Therefore, in aberrant Wnt 
signaling pathways β-catenin is free to shuttle into the nucleus and promote pro-
oncogenic and pro-angiogenic events18.  
 
1.3 The Novel Role of c-Cbl in β-catenin Regulation 
Casitas B-lineage lymphoma (c-Cbl) is a cytosolic adaptor protein with a ring-
finger type E3 ligases19. Emerging evidence has demonstrated that it inhibits 
physiological and pathological angiogenesis20 by serving as a unique E3 ligase that 
targets nuclear active β-catenin independently from the destruction complex6. Chitalia et 
al. demonstrated in endothelial cells that Wnt also induces c-Cbl nuclear translocation 
thereby ensuring active β-catenin ubiquitination even in the Wnt-on phase6. Furthermore, 
the anti-oncogenic potency of c-Cbl has also been elucidated through the interaction of its 
RING finger domain with other substrates21,22. The binding of UbcH7 to the RING finger 
domain on c-Cbl allows for the ubiquitination of epidermal growth factor receptor 
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(EGFR) and subsequent proteosomal degradation21. Conversely, a naturally occurring 
oncogenic mutant with deletion of 17 amino acids near the N-terminus of the c-Cbl RING 
finger known as 70Z-Cbl isoform, fails to degrade EGFR21. The resulting escalation in 
EGFR has been associated with tumor growth and progression, and has also been used as 
a reliable diagnostic marker for cervical, breast and colorectal cancers23. 
 
1.4    Cbl History, Structure and Function 
The identification of the Cbl protein family originated with the discovery of v-
Cbl, a truncated homologue of the larger cellular c-Cbl4, that was first observed to induce 
myelogenous leukemia in mice infected with the Cas NS-1 retrovirus24. In mammals 
three genes c-Cbl, cbl-b, and cbl-c make up the Cbl family24. Their respective proteins 
differ in the number of amino acids present in their C-termini, with Cbl-c being the 
shortest isoform4. Both c-Cbl and Cbl-b are primarily cytosolic adaptor proteins that 
influence an estimated 150 proteins25.   
The N-terminus region (including the tyrosine binding, linker and RING domains) 
of both c-Cbl and Cbl-b is highly conserved, and allows for Cbl to function as an 
effective E3 ubiquitin ligase (Figure 2) 25. Although the C-terminus is less conserved 
between the two isoforms25, an imperative mutual function of the respective proline rich 
regions located on the C-termini is to serve as docking sites for and SH3 (Src homology 
3) domain-containing proteins26. This allows for Cbl proteins to serve as adaptor 
molecules and negative regulators19 within a wide range of signal transduction pathways, 
further illustrating the critical role ubiquitination by Cbl proteins play in determining the 
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fate of oncoproteins and Src kinase activity27,28. Furthermore, the proline rich regions of 
c-Cbl have also been shown to target activated Src for proteosomal degradation29, thereby 
providing a larger body of evidence to support the more dominant role played by c-Cbl in 
oncogenic regulation, while ubiquitination by Cbl-b does not always result in 
proteosomal degradation19.  
 
 
Figure 2| The structure of the various Cbl isoforms. All three isoforms contain a RING domain and the 
Tyrosine Kinase Binding Domain around the N-terminus, while Cbl-c lacks the proline rich regions. 
Additionally the tyrosine phosphorylation sites only found on both c-Cbl and Cbl-b, where Y700 and 774 
on c-Cbl have counterparts on Cbl-b (Y665 and Y709). However, Y731 is exclusively found on c-Cbl, 
giving rise to its unique function as an E3 ligase. Figure taken from Swaminathan, et al. 200624 
 
Even though c-Cbl has been shown to be a negative regulator of downstream 
cellular signaling pathways through the process of ubiquitination, recent evidence has 
demonstrated that c-Cbl is susceptible to inhibition by ubiquitination as typified in the 
presence of active Src30. In the presence of Src the tyrosine residues on c-Cbl are 
phosphorylated allowing for the initiation of c-Cbl ubiquitination and consequent 
degradation19. The precise mechanism that permits the dual nature of the phosphorylated 
tyrosine residues to function as E3-ligases and determinants of the protein's fate remains 
elusive19.  
Furthermore, there are proteins like Src-like adaptor
protein (SLAP) and tubulin whose binding to Cbl is not
compromised by inactivation of the SH2-like domain of
c-Cbl, which abrogates direct binding to PTKs (Tang
et al., 1999; Teckchandani et al., 2005a). These findings
argue that TKB is capable of multiple interactions with
its binding partners, and some of these interactions are
likely to be entirely independent of the modified SH2
domain of c-Cbl.
Another highly conserved region of c-Cbl is a C3HC4
Zinc-binding RING finger domain, which mediates the
E3ubiquitin ligaseactivity of c-Cbl (Joazeiro et al., 1999;
Levkowitz et al., 1999). The two domains are inter-
spersed by a short linker sequence, which is crucial for
ubiquitin ligase activity of c-Cbl; various mutations in
this region render c-Cbl transforming (Thien et al.,
2001). TKB and RING act in concert to facilitate
ubiquitylation and degradation of activated PTKs, with
theTKBdomain conferring substrate specificity and the
RING finger bringing in an E2 biquitin-conjugating
enzyme.
The divergence in domain structure manifests in the
C-terminus of Cbl proteins. While c-Cbl, Cbl-b, and
D-CblL (Drosophila homolog of Cbl) have extensive
proline-rich regions containing a number of putative
SH3-bindingmotifs (Langdon et al., 1989b; Keane et al.,
1995; Robertson et al., 2000), Sli-1 (Caenorhabditis
eleganshomolog), andCbl-3havevery short proline-rich
regions (Yoon et al., 1995; Keane et al., 1999; Kim et al.,
1999) and the short form of D-Cbl has none (Hime
et al., 1997). Recently, a novel proline-arginine motif
(PXXXPR), specifically recognized by the SH3-contain-
ing protein CIN85 was identified in c-Cbl (Kowanetz
et al., 2003; Kurakin et al., 2003) and Cbl-b (Szymkie-
wicz et al., 2002). The C-terminal part of Cbl proteins
also contains the major sites of tyrosine phosphoryla-
tion, which enable interactions of Cbl with SH2 domain-
containing proteins (see below). The C-terminus of
c-Cbl, Cbl-b, and D-CblL contains a sequence homo-
logous to both the leucine zipper (LZ) and the ubiquitin-
associated (UBA) domain. The LZ domain mediates
dimerization of multiple proteins (Busch and Sassone-
Corsi, 1990; Alber, 1992), while UBA binds to ubiquitin
residues (Bertolaet et al., 2001; Chen et al., 2001;
Wilkinson et al., 2001). Although these structural
elements superimpose inside the Cbl sequence, their
functions can be dissociated, since homo- and hetero-
dimerization has been shown for both c-Cbl and Cbl-b
(Bartkiewicz et al., 1999; Liu et al., 2003), while only
Cbl-b and not c-Cbl can bind to ubiquitin through its
UBA domain (Davies et al., 2004). Whereas dimeriza-
tion of Cbl appears to play a role in its protein–protein
interactions and phosphorylation (Bartkiewicz et al.,
1999; Liu et al., 2003), the role of UBA-mediated
binding to ubiquitin is less clear, since UBA is not
essential for Cbl-mediated ubiquitylation (Levkowitz
et al., 1999).
GENOMIC ORGANIZATION
Cbl genes in multiple species have been identified. A
recent work by Nau and Lipkowitz (2003) presents the
intron-exon structure of human Cbl genes and their
evolution in detail. Thus, c-cbl has an open reading
frame of 16 exons, cbl-b has 19 exons and cbl-c has 11
exons. The human and mouse forms of cbl-b and c-cbl
have identical intron/exon structure, while in cbl-c it
extends to exon 7 and diverges after that. In accordance
with known facts about conserved sequences among Cbl
proteins, the first 430 amino acids of the three members
of the human Cbl family display a high degree of
homology. This spans the TKB domain, the RINGfinger
domain and the linker between the two. The splice sites
in this region, which includes the first intron/exon
junction to the ends of exon 8 for c-Cbl, exon 9 for Cbl-b,
and exon 7 for Cbl-c, occur within the same amino acid
codon at the same nucleotide positions. This relation-
ship between Cbl family members is also true for mouse
Cbl proteins. The similarity tapers at the 50and30 ends of
the genes.
Among the non-mammalian species, Cbl genes are
present in roundworms, fish, frogs, and birds. Round-
worms (C. elegans) have a single Cbl protein (Sli-1).
Insects have one cbl gene, which gives rise to two splice
forms in Drosophila. Fish, amphibians, and birds have
both c-Cbl and Cbl-b. Mammals, including humans,
mice, rats, cows, and pigs, have genes encoding c-Cbl,
Cbl-b, and Cbl-3 (Cbl-c), although in some species only
partial Cbl sequences are available. Two alternative
splice forms of human Cbl-b exist in addition to its full-
length form. In one of these two forms, a termination
codon immediately after the splice generates a protein
172 amino-acid shorter than full-length Cbl-b. In the
second form, there is a 113-bp unique sequence inserted
at the site of an alternative splicing and a termination
codon 14 bp after the splice site makes it shorter by 213
amino acids (Keane et al., 1995). Likewise, two splice
forms exist for Cbl-3; they are designated Cbl-3L (long
form) and Cbl-3S (short from). The latter lacks 46 amino
acids in the TKB domain, including Gly-306 (Keane
et al., 1999).
Fig. 1. Structural organization of human Cbl proteins: The
N-terminal portion encompasses the tyrosine kinase binding (TKB)
domain and RING finger domain, and the linker region between them;
this portion of Cbl is well conserved. G306E and C381A are point
mutations that inactivate the functio ing of the TKB and RING
domain, respectively. The C-terminal portion includes an extensive
proline-rich region in c-Cbl and Cbl-b, while being rudimentary in Cbl-
c/Cbl-3. Also, present in the C-terminus of c-Cbl and Cbl-b, but absent
in Cbl-c are a number of tyrosine residues; Tyr-700, -731, and -774
represent the major sites phosphorylated by PTKs in c-Cbl. Tyr-665
and -709 of Cbl-b correspond to Tyr-700 and -774 of c-Cbl, while Tyr-
731 is unique to c-Cbl. The ubiquitin associated domain (UBA) and
leucine zipper (LZ) structurally superimpose in c-Cbl and Cbl-b. Refer
to the text for a more detailed explanation.
22 SWAMINATHAN AND TSYGANKOV
Journal of Cellular Physiology DOI 10.1002/jcp
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Nevertheless the phosphorylation of tyrosine residues on c-Cbl and Cbl-b remains 
an important contributor to the E3-ligase capability of the protein as it permits binding of 
SH2 (Src homology 2) domain-containing proteins31. Tyrosine residues 700 (Y700) and 
774 (Y774) on c-Cbl and residues 709 and 665 on Cbl-b share similar amino acid 
sequences32 which therefore functions to allows the two proteins to bind similar SH2 
domain-containing proteins25. For example it has been shown that Vav, a guanine 
nucleotide exchange factor protein transcribed from the proto-oncogene VAV, with 
associations in the activation of the Ras pathway in hematopoietic cell lines33, is recruited 
by and binds to Y700 on c-Cbl31. Furthermore, it has also been demonstrated that in 3T3-
L1 adipocytes stimulated by the hormone insulin promotes the association of Crk on c-
Cbl34, specifically binding to tyrosine residues 700 and 77435. Tyrosine kinases from the 
Src family, such as Lyn, Fyn and Yes25 are known to phosphorylate residues Y700, Y731 
and Y774 on c-Cbl36.  
 
1.5 The Unique Role of Tyrosine Residue 731 on c-Cbl 
Interestingly a key distinguishing factor in the nearly identical roles played by c-
Cbl and Cbl-b stems from tyrosine residue 731 (Y731) on c-Cbl31. Unlike residues Y700 
and Y774, Y731 does not share homology on Cbl-b37 and remarkably does not share 
common amino acid sequences with either Y700 and Y77438. This unique characteristic 
of Y731 implies that it serves biological functions that potentially differ from its 
counterparts31. Evidence has been presented, demonstrating that Y731 recruits and binds 
to the SH2 domain of the p85 regulatory subunit constituting phosphatidylinositol-4,5-
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bisphosphate 3-kinase (PI3K)19,31 and promotes the recruitment of PI3K to the cell 
membrane37. The importance of the PI3K lipid kinase family is highlighted through its 
essential role in the PI3K/Akt signal transduction pathway39, where the phosphorylation 
of 3'-hydroxyl group of phosphoinositides by PI3K yields a range of substrates, notably 
the second messenger phosphaidylinositol-3,4,5-trisphosphate (PIP3)40. Crucially PIP3 
recruits and phosphorylates protein kinase B (Akt) at the cell membrane41, where upon 
activated Akt functions in maintaining cellular functions such as survival and 
proliferation42, through the phosphorylation of further downstream substrates39. Diseases 
such as diabetes and autoimmune conditions have been revealed to stem from PI3K 
pathway mutations39, moreover PI3K-Akt pathway anomalies are the most common 
pathways leading to the development and progression of cancer40. The role of c-Cbl in 
the regulation of downstream Akt activation, although not studied in detail19, posses the 
potential to pave the way for novel targeted therapies.  
Recently, tyrosine residue 731 on c-Cbl has also been show to play a specific 
regulatory role in nuclear translocation and subsequent activation of β-catenin43. In the 
presence of Wnt ligand, phosphorylation of Y731 occurs which in turns promotes the 
dimerization of c-Cbl43. The consequent Wnt-induced dimerization of c-Cbl allows the 
protein to translocate into the nucleus and function as a negative regulator of β-catenin 
activity43. Additionally, Y731 activation has also been shown to negatively regulate Wnt 
target pro-angiogeneic genes such as interleukin 8 (IL-8) and VEGF, further exacerbating 
the clinical potential that c-Cbl gene target therapy can provide in inhibiting 
tumorigenesis and metastasis43.  
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Figure 3| The role of c-Cbl in determining the fate of nuclear β-catenin with respect to the Wnt/β-catenin 
pathway. During the Wnt off phase (i.e. in the absence of Wnt ligand) β-catenin is in the phosphorylated 
state, allowing it to associate with the APC destruction complex resulting in its degradation. However, in 
the Wnt on phase (i.e. in the presence of Wnt ligand) β-catenin escapes phosphorylation and the destruction 
complex, thereby translocating to the nucleus where it promotes transcription of target genes. Jointly c-Cbl 
is also phosphorylated in the presence of Wnt, providing c-Cbl the unique function of degrading active β-
catenin, even in the absence of the destruction complex. Phosphorylation of c-Cbl at tyrosine residue 731 
promotes the dimerization of c-cbl and its consequent translocation into the nucleus. Figure taken from 
Shivanna, et al. 201543 
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1.6 Thesis Objective  
Aberrant hyperactive Wnt signaling due to accumulation of nuclear active β-
catenin contributes to CRC pathogenesis in almost all sporadic CRC patients. Given the 
importance of the phosphorylated tyrosine residues in regulating c-Cbl binding and down 
regulation of β-catenin6,30,43,44, we hypothesize that the phosphorylation of tyrosine 
residues 700,731 and 774 plays an intricate part in determining CRC cell survival 
dependent upon cell Wnt signaling status, which in turn is mediated through mutations in 
β-catenin or adenomatosis polyposis coli (APC).  
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2. MATERIALS AND METHODS 
 
2.1 Cell Culture Maintenance 
Four colorectal (CRC) cell lines were examined on the basis of their respective Wnt 
signaling status (Wnt-on or Wnt-off) and individual mutations in β-catenin and or 
adenomatosis polyposis coli (APC) as shown in the following table. 
 
Table 1| Wnt Status and Oncogenic Mutations in CRC cell lines  
 
 
Wnt status Cell lines  Types of mutations in Wnt and RAS pathway 
genes 
Wnt off RKO Wild-type APC, β-catenin and EGFR, wild-type 
KRAS but mutant BRAF 
Wnt-on HCT116 Phosphorylation-resistant S33A β-catenin, wild-
type EGFR and mutant KRAS 
HCT15 and DLD1 Loss of function APC mutation resulting in 
active β-catenin, mutant KRAS  
 
 
RKO cell line is wild-type (WT) β-catenin and APC and Wnt-off, DLD1 and HCT 15 
cell lines are mutant APC and Wnt-on, and HCT 116 cell line is mutant β-catenin and 
Wnt-on. Each cell line was grown in cell culture dishes cultured with Dulbecco’s 
modified Eagle’s medium (DMEM) containing 4.5 g/L glucose and L-glutamine but 
without sodium pyruvate (Corning) accompanied with 10% fetal bovine serum (FBS) 
(Life Technologies) and 5% penicillin, streptomycin (Life Technologies). Cells 
underwent a change of media, approximately, every two days and were incubated at 37oC 
with 5% CO2. 
11 
 
2.2 Luciferase Assay to Determine Endogenous Wnt Activity 
Parental cell lines seeded in 6 well plates stably transduced with pBARLS and 
pfuBARLS plasmids (obtained from Randy Moon Lab) expressing puromycin resistant 
genes. The stable cells lines were lyzed in passive lysis buffer once cells achieved 80% 
confluence post transduction and luciferase assay using dual luciferase assay was 
performed on cells per manufacturer’s instructions (Promega). The protein content was 
examined using Bradford assay. The luciferase reading was normalized to protein content 
(relative luciferase unit- RLU). The mean value of 3 experiments was calculated and 
student's t-test was applied to asses the significance of the data. 
 
2.3 Generation of Stable Phosphorylation Inactive Mutants Through 
Retroviral Transduction  
Once the parental cell lines achieved a level of 80-90% confluence they underwent 
passaging and transferred to individual 12 well plates (Falcon) and prepped for retroviral 
transduction. Cells continued to grow in DMEM media with 4.5g/L glucose and L-
glutamine but without sodium pyruvate. At 70% confluence lenti viral transduction was 
initiated. Viral particles containing wild-type c-Cbl (WT), a FLAG-tag sequence (control) 
without a c-Cbl construct served as a negative control. c-Cbl with different phospho-
inactive mutants were generated using cloning. Tyrosine residues were changed to 
phenylalanine 700, 731, 774, all of which represent phospho-inactivating mutations. All 
retroviral particles were FLAG-tagged for easy detection and immunoprecipitation.  Each 
12 
 
construct included a puromycin resistant gene to positively select virally transduced cells 
from non-infected ones.  
Cells were transduced (day 0) using 20µl of concentrated virus complemented with 0.5µl 
polybrene (Santa-Cruz Biotechnology) to enhance viral transduction efficiency and 500µl 
of DMEM media containing 4.5 g/L glucose and L-glutamine but without sodium 
pyruvate. Cells were incubated at 37oC with 5% CO2 overnight. Following overnight 
incubation period (day 1), the cells underwent a change of media to remove any 
unincorporated virus, and replenished with 1ml of fresh DMEM media containing 4.5 g/L 
glucose and L-glutamine but without sodium pyruvate. On day 2 cells were positively 
selected with the addition of puromycin (Life Technologies) to the media. Puromycin 
was diluted from a stock concentration of 10mg/ml to 1µg/µl. Each cell line required a 
different concentration of puromycin to effectively select transduced cell from non-
transduced ones.  Stable cell lines were maintained in the incubator at 37oC with 5% CO2. 
 
Table 2| Puromycin concentration for CRC cell lines 
Cell line Amount of puromycin (µg/µl) 
RKO 2 
DLD1 2 
HCT 15 8 
HCT116 2 
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2.4 Whole Cell Lysis 
Upon reaching 80% confluence cell cultures were placed on ice and gently washed 
twice with cold 1X phosphate buffered saline (PBS) (Boston Bioproducts). Cells were 
lysed using buffer containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS (Boston Bioproducts) administered with complete 
protease inhibitor table without EDTA (Roche) and phenylmethanesulfonylfluoride 
(PMSF, 1µl/ml).  Cells rested on ice for 30minutes, and lysate was collected into 
eppendorf tubes. Samples were boiled at 95oC in 2X Laemmli buffer (Boston 
Bioproducts), prepared in 1 part Laemmli 4X and 3 parts β-mercaptoethanol for 5 
minutes. To prevent protein degradation all lysate was stored at -20oC.  
2.5 Digitonin Extraction of Cytosolic β-catenin6 
Cells were washed twice with cold PBS inside cell culture plates and covered with 
digitonin buffer consisting of 120 mM KCl, 5 mM KH2PO4, 10 mM HEPES, pH 7.4, 2 
mM EGTA, 0.15 mg/ml digitonin (Sigma).  The plates were gently rocked on ice for 15 
min at 4oC.  The supernatant, the majority comprising of cytoslic proteins, was then 
aspirated and collected into eppendorfs, boiled for 5 minutes at 95oC and stored in -20oC. 
The remaining cells left on the cell culture plates were then scrapped using the RIPA 
protocol (see subsection 2.4) 
2.6 Immunoprecipitation Assay (IP) 
To inhibit protein phosphatase activity within cells, incubation for 45 minutes with 
activated sodium orthovanadate (Na3VO3) prior to harvesting was conducted. The 
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required 1mM (final concentration) of activated Na3VO3 was diluted from 200mM stock 
solution, by the addition of 25µl Na3VO3 to 5ml cell culture media.  
Cells were placed on ice and washed twice with cold 1X PBS followed by the 
addition of gentle lysis buffer (proteosomal inhibitor table already administered) in the 
absence of ionic detergents such as sodium deoxycholate and SDS.  PMSF was added to 
the gentle lysis buffer (5µl/ml).  
Lysate was probed with 1µg/µl of anti-flag antibody diluted from a stock solution of 
2µg/µl with gentle lysis buffer. The antigen-antibody complex was placed on a rotor and 
allowed to spin for 1 hour at 4oC. 60µl of Protein A/G PLUS-Agarose (sc-2003, Santa-
Cruz Biotechnology) slurry containing 50% PBS and 50% protein A/G was added to the 
eppendorfs to co-immunoprecipitate the flag antibody overnight at 4oC. Beads were 
vortexed localizing them at the bottom of each eppendorf and resuspended with 1ml 
gentle lysis buffer. After three washes the supernatant was discarded and 50µl of 2X 
laemmli buffer (diluted from 4X with gentle lysis buffer) was added to every eppendorf 
and boiled at 95oC for 5 minutes.  
2.7 Western Blot Analysis  
Braford assay was used to quantitate protein content in the sample. All protein 
measurements were conducted using optical density (OD:595) readings and compared to 
a preset standardized regression curve to determine the optimal amount of µg protein to 
load  in each well for SDS-polyacrylamide gel electrophoresis (PAGE). In general 25-
75µg of protein was loaded.  
15 
 
Samples were run on a 10% gradient polyacrylamide gel, and transferred to 0.2µm 
nitrocellulose membrane (Bio-Rad) for 1 hour at 4oC. The nitrocellulose membrane was 
blocked at room temperature in 5% milk made with PBS and 0.1% Tween-20 (PBS-T) 
(American Bioanalytical) for RIPA samples or 5% bovine serum albumin (BSA) 
consisting of 1X TBS and 0.1% Tween-20 (TBS-T) (American Bioanalytical) for 
immunoprecipitation samples, as the phosphate in milk can obstruct visualization of 
protein phosphorylation sites. The nitrocellulose membrane was washed 3 times for 10 
minutes in either PBS-T (for RIPA samples) or TBS-T (for immunoprecipitation 
samples), and then probed with the appropriate primary antibody overnight at 4oC (for 
RIPA samples) or for 48 hours (for immunoprecipitation samples). The primary antibody 
was diluted following the manufacturers recommended dilution factor. Following the 
removal of the primary antibody, the membrane was washed 3 times for 10 minutes and 
probed with horseradish peroxidase-conjugated (HPC) secondary antibodies coupled with 
1% milk containing 1X PBS-T (for RIPA samples) or 1% BSA containing 1X TBS-T for 
immunoprecipitation samples. Finally the membrane underwent 3 washes for 10 minutes.  
Membranes were developed using enhanced chemiluminescence (ECL) Western 
Blotting Substrate (Pierce Laboratories) according to the manufacturer’s instructions and 
relative band intensities were quantitatively analyzed through densitometry (using ImageJ 
software developed by National Institute of Health). 
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2.8 Antibodies 
Mouse monoclonal Flag-tag, β-actin, β-catenin were from Cell Signaling and 
diluted according to manufacturers recommended dilutions. Rabbit monoclonal 
phosphorylation specific antibodies (Y700, Y731, Y774), c-Cbl, EGFR and 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibodies were also used 
from Cell Signaling. Goat anti-mouse and anti-rabbit HRP conjugated secondary 
antibodies were from Bio-Rad 
2.9 MTT Cell Survival Assay 
Cells were seeded in two 96 well plates at a concentration of 2000 cells/ml in 
each well with DMEM media containing 4.5 g/L glucose and L-glutamine but 
without sodium pyruvate accompanied with 10% fetal bovine serum (FBS) (Life 
Technologies) and 5% penicillin, streptomycin (Life Technologies). One plate would 
be analyzed after 24-hour incubation period and the other plate after 48-hour 
incubation period following serum stimulation. Both plates underwent a 24 hour 
incubation period at 37oC with 5% CO2 cells under serum starved conditions using 
plain DMEM media without FBS, antibiotic was kept to reduce chances of 
contamination.  The following day the cells were serum stimulated for 2.5 hours 
followed by a 24 hours period of serum starvation, unless otherwise stated, in the 
following conditions: 
• Serum stimulation in plain DMEM media with 5% FBS not followed by 
serum starvation  
• Serum stimulation in plain DMEM media with 5% FBS 
17 
 
• Wnt 3a ligand stimulation diluted in plain DMEM media. Wnt3 ligand 
was diluted from a stock concentration of 10ng/µl to 0.1ng/µl for DLD1 
and HCT 15 cell lines, and 0.05ng/µl for RKO cell lines  
• Wnt 3a + DKK diluted in plain DMEM media serum stimulation. DKK 
was used at a concentration of 0.5ng/µl, diluted from a stock solution of 
50ng/µl 
• Staurosporine (a potent pro-apoptotic agent) diluted in plain DMEM 
media, to induce apoptosis. Staurosporine was used at a concentration of 
1µM, diluted from stock concentration of 1mM 
• Control condition, consisting of plain DMEM media without FBS carried 
on until plates were analyzed  
AlamarBlue® (Bio-Rad) dye was then added to each well at a volume of 5µl 
accompanied with 45µl of plain DMEM media. Plates were analyzed using a 
microplate spectrophotometer at a reference wavelength of 600nm and measurement 
wavelength of 570nm at 2 hours intervals, twice. Duplicate results were averaged and 
the significance of the data determined using the Student t-test method. The condition 
that yielded the greatest change in survivability in the cells between empty and WT 
constructs was then carried forth in a separate MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay where full set lenti viral constructs were assessed 
(empty, WT, Y700F, Y731F and Y774F) to determine if point directed c-Cbl tyrosine 
phospho-mutagenesis effected cell survival.  
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 2.10 Clonogenic Cancer Colony Formation Assay 
A total of 50,000 CRC cells were seeded in 24-well low-adhesion plates 
(Corning) and allowed to grow for 3 days. Images were obtained using same 
microscope set up at 4X magnification. The samples in triplicate were analyzed 
and representative images are shown.   
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3. RESULTS 
 
 
We hypothesized that the phosphorylation of tyrosine residues 700,731 and 774 plays 
an intricate part in determining CRC cell survival, which is in part mediated through 
mutation in β-catenin or adenomatosis polyposis coli (APC). This hypothesis stems from 
two major pretexts: 1. Pro-oncogenic activity of nuclear active β-catenin in CRC 
pathogenesis and 2. Importance of the phosphorylated tyrosine residues in determining 
the binding and regulation of nuclear tumorigenic β-catenin 6,30,43,44   
3.1 Differential Wnt Activity in CRC Cell Lines  
Different CRC cell lines carry mutations in the different components of the Wnt 
signaling pathway. Therefore, we first examined the Wnt activity in different cell lines. 
Our intention was to examine the c-Cbl phosphorylation in CRC cell lines sorted 
according to their Wnt status. CRC cells were transduced stably expressing a promoter-
luciferase reporter construct (pBAR) or a mutant construct (pfuBAR). The luciferase 
reading was normalized to protein content called relative luciferase unit (RLUs). HCT 15 
exhibited at least 1.7 times higher Wnt activity compared to other cell lines (Figure 4) as 
shown by pBAR, while RKO showed the lowest endogenous Wnt activity. Both DLD-1 
and HCT 116 cell lines presented Wnt activity levels in between..  
In light of the differential expression of Wnt activity the panel of CRC cell lines were 
assigned as biologically Wnt-on (HCT 15, HCT 116, DLD) or Wnt-off (RKO). 
Furthermore CRC cells were lysed to determine endogenous c-Cbl activity (Figure 5) in 
accordance with their respective Wnt expression pattern. The Wnt-off cell line (RKO) 
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exhibited the highest c-Cbl expression , compared to the Wnt-on cell lines (DLD-1, HCT 
15, HCT 116).  
 
 
 
 
Figure 4| Differential Wnt Activity in CRC Cell Lines. CRC cell lines stably 
transduced with pBAR (positive response to β-catenin) and pfuBAR (no 
response/control) plasmids expressing puromycin resistant genes. Luciferase  assay was 
conducted to determine levels of Wnt activity as a product of nuclear β-catenin activity. 
All cell lines showed significant increase in Wnt activity with HCT 15 (p=9x10-5) 
expressing the highest levels of Wnt activity and RKO (p=1x10-4) the lowest. 
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Figure 5| c-Cbl Expression Levels in Wnt-On and Wnt-Off CRC Cell Lines.  CRC 
cells were lyzed and probed with endogenous c-Cbl to determine expression levels. Wnt-
off cell line (RKO) showed the thickest band compared to Wnt-on cell lines. GAPDH 
was used as a loading control 
. 
3.2 Dissimilar Phosphorylation of Tyrosine Residues (700, 731 and 774) in 
Wnt-on and Wnt-off Cell lines 
Stably expressing CRC cell lines expressing either exogenous c-Cbl (Flag-tag) or 
empty vector (control) were immunopercipitated and probed with respective c-Cbl 
phospho-antibodies (Y700, Y731 Y774). The input indicates that comparable levels 
of c-Cbl were precipitated from all the CRC cell lines, however the phosphorylation 
pattern exhibited interesting dichotomy (Figure 5). Wnt-off cell line (RKO) had the 
highest amount of phosphorylation on all three tyrosine residues (700,731 and 774), 
while Wnt-on cell lines (HCT 15, HCT 116 and DLD1) had the lowest level of 
phosphorylation.   
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Figure 6| Variable Phosphorylation Levels on Tyrosine Residues in Wnt-On and 
Wnt-Off Cell Lines. Stably expressing CRC cell lines (Control or Flag-tagged c-Cbl) 
were lysed and immunoprecipitated using Flag antibody, and then probed with antibodies 
against the respective phosphorylation residues. Despite equal quantity of 
immunoprecipitated c-Cbl, Wnt-off cell line (RKO) exhibited higher amount of tyrosine 
phosphorylation at residues 700, 731 and 774 compared to Wnt-on cell lines. 
 
3.3 Expression of c-Cbl Constructs  
 Next, we examined the biological significance of c-Cbl phosphorylation by 
generating phospho-inactive mutants.  In order to determine whether c-Cbl constructs 
were successfully expressed in the CRC cells, we lysed the cells and probed the lysate for 
Flag-tag, since all the constructs express Flag-tag. Figures 6 and 7 demonstrate that in the 
DLD-1 (Wnt-on) and RKO (Wnt-off) cell line exogenous c-Cbl expression is confirmed 
in the WT and all phospho-mutant constructs, but is not present in the control.  
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Furthermore, the density of the band in the Y731F mutants for DLD-1 (Figure 6) is less 
compared to the WT and other phospho-mutants. In contrast, Figure 7 shows that the c-
Cbl expression in the Y731F mutant for the RKO cell lines is greatest compared to the 
other phospho-mutants.   
 
 
 
Figure 7| Confirmation of Virally Transduced c-Cbl Constructs in DLD-1 Cell 
Lines, Tagged with Flag. In order to determine the functional significance of c-Cbl in 
CRC cell survival between Wnt-on and Wnt-off cell lines, we introduced phospho-
inactive c-Cbl mutants (tyrosine mutated to phenylalanine) targeting the three major c-
Cbl tyrosine kinases phosphorylation residues (Y700, Y731 Y774).. 
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Figure 8| Confirmation of Virally Transduced c-Cbl Constructs in RKO Cell Lines, 
Tagged with Flag. In order to determine the functional significance of c-Cbl in CRC cell 
survival between Wnt-on and Wnt-off cell lines, we introduced phospho-inactive c-Cbl 
mutants (tyrosine mutated to phenylalanine) targeting the three major c-Cbl tyrosine 
kinases phosphorylation residues (Y700, Y731 Y774). The top western blot shows a long 
exposure illustrating WT c-Cbl, the bottom western blot is a shorter exposure period 
showing phopsho-mutant c-Cbl expression (Y700F, Y731F, Y774F). 
 
 
 
3.4 MTT Assay Reading 
We examined the CRC cell viability using MTT assay. This assay is based on the 
principle that viable cells metabolize the dye resulting in a color change, which correlates 
with cell viability. The color change is caused by the viable cells that are able to activate 
NAD(P)H-dependent cellular oxidoreductase enzymes. The enzymes reduce the dye to an 
insoluble form (formazan), a product with a purple color. The CRC cells lines were 
subjected to MTT assay in 96-well format. Before analyzing the entire set of c-Cbl 
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mutants, we first optimized the conditions for the MTT assay that would yield a 
difference between control and wild-type c-Cbl. Four different conditions were used as 
shown in section 2.9 of the Materials and Methods. 
The conditions were examined for 24 hours and 48 hours. In DLD-1 cell line, the data 
indicates (Figure 8 A & B) that the cells not stimulated with serum exhibited significant 
different between control and wild-type c-Cbl. The wild-type c-Cbl significantly reduced 
DLD-1 cell viability. This different persisted for both 24 hours and 48 hours. 
 
 
 
 
 
Figure 9 A| Decrease in Viability for DLD-1 Cells expressing WT c-Cbl at 24 (A) 
and 48 (B) Hours. A range of conditions were introduced within cell cultures to 
determine which condition would result in the clearest change in viability between empty 
and WT c-Cbl expressing cells. The control condition (plain media without FBS 
stimulation) showed a significant decrease in the viability of cells. An average of 6 
independent samples are shown. Error bar= SEM. Compared to empty p=0.02 for WT 
after  24 hours, and p= 0.005 WT after 48 hours. 
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Figure 10 B| Decrease in Viability for DLD-1 Cells expressing WT c-Cbl. A range of 
conditions were introduced within cell cultures to determine which condition would 
result in the clearest change in viability between empty and WT c-Cbl expressing cells. 
The control condition (plain media without FBS stimulation) showed a significant 
decrease in the viability of cells. An average of 6 independent samples are shown. Error 
bar= SEM. Compared to empty p=0.02 for WT after 24 hours, and p= 0.005 WT after 48 
hours. 
 
Having defined the condition that yields difference between the control and wild-
type c-Cbl, we examined DLD-1 viability using cell lines stably expressing different 
phospho-mutants (Figure 9). The data shows that wild-type c-Cbl significantly inhibited 
DLD-1 cell viability, consistent with the above experiment. The phospho-mutants on the 
other hand exhibited a differential pattern. While Y700F and Y774F behaved like wild-
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type c-Cbl, Y731F had no effect on cell viability; on the contrary it enhanced DLD-1 cell 
viability (though this increase was not statistically significant)  
 
 
 
Figure 11| The effect of tyrosine kinase inactivating mutations on CRC cell survival 
in Wnt-On CRC cells. WT c-Cbl expression significantly reduced the survival of DLD-
1 cell lines with Y700 and Y774 mutations demonstrating a similar trend. However Y731 
mutation has no effect on cell survival, highlighting the importance of Y731 on c-Cbl’s 
anti-oncogenic role in Wnt-on cell lines. An average of 6 independent samples is shown. 
Error bar= SEM. Compared to empty p= 2.30x10-7 for WT, p= 3.75x10-5 for Y700F, and 
p= 2.92x10-5 for Y774F 
 
 We then examined the effect of c-Cbl and its phosphorylation in Wnt-off RKO 
cell line.  As mentioned above, we first optimized the conditions for the  MTT assay in 
RKO cells that would yield a difference between control and wild-type c-Cbl (Figure 10). 
Four different conditions were used as shown in Section 2.9 of the Materials and 
Methods. 
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The conditions were examined for 24 hours and 48 hours. In RKO cell line, the 
data indicates that wild-type c-Cbl in all of the conditions significantly increased CRC 
cell survival (Figure 10). However, this difference was only observed in 24 hours 
samples.  
 
 
 
Figure 12| Increase in Viability for RKO Cells expressing WT c-Cbl. A range of 
conditions were introduced within cell cultures to determine which condition would 
result in the clearest change in viability between empty and WT c-Cbl expressing cells. 
All conditions minus the control and staurosporine conditions showed a significant 
increase in WT cell viability compared to empty. An average of 6 independent samples 
are shown. Error bar= SEM. For 24 hours, compared to empty p=2.97x10-6 for WT under 
5% FBS serum stimulation, p= 1.05x10-3 for WT under vehicle condition, p= 6.3x10-4 for 
WT under Wnt3A+DKK condition, p= 1.2x10-6 for WT under 5% FBS stimulation 
removed after 2.5 hours, p=3.8x10-6 for WT Wnt3A stimulation. The differences found 
after 24 hours (A) were nullified when read after 48 hours (B). 
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Figure 13| Increase in Viability for RKO Cells expressing WT c-Cbl. A range of 
conditions were introduced within cell cultures to determine which condition would 
result in the clearest change in viability between empty and WT c-Cbl expressing cells. 
All conditions minus the control and staurosporine conditions showed a significant 
increase in WT cell viability compared to empty. Average of 6 independent samples are 
shown. Error bar= SEM. For 24 hours, compared to empty p=2.97x10-6 for WT under 5% 
FBS serum stimulation, p= 1.05x10-3 for WT under vehicle condition, p= 6.3x10-4 for 
WT under Wnt3A+DKK condition, p= 1.2x10-6 for WT under 5% FBS stimulation 
removed after 2.5 hours, p=3.8x10-6 for WT Wnt3A stimulation. The differences found 
after 24 hours were nullified when read after 48 hours. 
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enhanced RKO cell viability, consistent with the above experiment. The phospho-mutants 
on the other hand exhibited no change in CRC survival.  
The data indicates that the wild-type c-Cbl increases CRC survival in cell lines 
not mutant in Wnt components (i.e. Wnt-off) and that all of the tyrosine phosphorylation 
sites are critical for RKO cell viability.  
 
 
 
 
Figure 14| The effect of tyrosine kinase inactivating mutations on CRC cell survival 
in Wnt-Off CRC cells. Expression of WT c-Cbl in cells demonstrated enhanced 
survival, while the expression of mutant c-Cbl had no effect on cell survival. Average of 
6 independent samples is shown. Error bar = SEM. Compared to empty p= 8.98x10-6 for 
WT. 
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3.5 WT c-Cbl inhibits colony formation, an effect contrary to Y731F  
 
We next examined how the effect of CRC cell viability translates into cancer 
colony/tumor formation. We performed a clonogenic colony formation assay in non-
adherent format. Of the examined cell lines, only HCT15 cell lines showed distinct 
colony formation. HCT15 cells stably expressing wild-type c-Cbl and different phospho-
mutants were used.  The data showed that WT c-Cbl expressing cells inhibited colony 
formation compared to control, while Y731F mutants showed enhanced colony formation 
in comparison to 700,and 774 phospho-mutants, (Figure 12).  
 
 
Figure 15| Clonogenic Colony Formation Assay. To determine whether c-Cbl regulates 
CRC proliferation in non-adherent format, clonogenic colony formation assay was 
performed Representative image of 3 replicates is shown  
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3.6 Effect of Phospho-Mutant on c-Cbl Target Genes 
 
 We then examined the possible molecular mediators of c-Cbl's effect on CRC 
viability. Though c-Cbl has several targets, we examined one of the most relevant and 
well studied c-Cbl targets, EGFR. EGFR, expression was analyzed to determine how 
phospho-mutants affected the level of expression. For Wnt-on cell lines (DLD-1) 
densitometry analysis (Figure 13) shows that Y731 mutants caused a 20% decrease in 
EGFR expression when compared to empty. On the other hand, WT, Y700F and Y774F 
showed a greater than 70% increase in EGFR expression. In Wnt-off cell lines (RKO) 
EGFR expression in all constructs was increased when compared to empty (Figure 13), 
with Y731 mutants showing a 5.8 times increase in expression, followed closely by Y700 
mutants which showed a 5 times increase in EGFR expression.  
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Figure 16| Difference in c-Cbl target gene (EGFR) Expression Among c-Cbl 
Constructs in Wnt-On and Wnt-Off Cell Lines. Western analysis shows that EFGR 
expression decreased in Wnt-on cell lines (top) expressing Y731 c-Cbl mutant. EGFR 
expression was increase in Wnt-off  cell lines (bottom) for all constructs. Actin was used 
as a loading control. 
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4. DISCUSSION  
 
 
Previous studies have illustrated the important role played by c-Cbl in regulating 
active nuclear β-catenin in endothelial cell lines43 and as an inhibitor of 
angiogenesis6. Though the role of tyrosine residue 731 in regulating c-Cbl's biological 
function was evident in those cells, this study further extends those observations in 
CRC cells and shows the regulatory role of c-Cbl phosphorylation at tyrosine residue 
700, 731 and 774 in Wnt-off CRC cell lines and the novel anti-oncogenic role 
phosphorylation of Y731 plays in Wnt-On CRC cell lines. 
Our results demonstrate that c-Cbl phosphorylation is present in both Wnt-on and 
Wnt-off CRC cell lines (Figure 6). However, the levels of phosphorylation exhibit a 
differential pattern dependent on the level of Wnt signaling expressed by cells (Figure 
4 and 6). Furthermore, this finding holds constant when analyzing the levels of 
endogenous c-Cbl expression levels. In cells expressing greatest Wnt activity (HCT 
15), endogenous c-Cbl levels are found to be the lowest (Figure 5), when compared to 
cells expressing the lowest levels of Wnt activity (RKO). This finding demonstrates a 
pattern in the effect of Wnt signaling on c-Cbl hinting towards a regulatory role 
played by c-Cbl in the maintenance of low Wnt signaling levels in CRC cell lines. 
Although c-Cbl has been shown to mediate its effects on Wnt signaling through β-
catenin in endothelial cell lines43, further work is required to extend this hypothesis's 
relevance in cancer. 
c-Cbl significantly inhibited cell survival in Wnt-on CRC cell lines (Figure 8), 
supporting its role as a tumor suppressor. However, c-Cbl expression also enhanced 
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the survival of Wnt-off cells (Figure 10), supporting its role as a proto-oncogene. 
These results convey a possible two-fold nature of c-Cbl, which is dependent on a 
cell's signal transduction expression, in this case specifically endogenous Wnt 
signaling levels. It is also plausible that the enhanced survival demonstrated by RKO 
cells when expressing c-Cbl was a result of a dominant negative effect. Since the 
baseline expression of c-Cbl in those cells was already high, artificially 
overexpressing c-Cbl could have resulted in the down-regulation of c-Cbl function 
and thus increased survival.  
Our results indicate that phosphorylation of tyrosine residue 731 is a critical 
component regulating Wnt-on cell survival (Figures 9 and 12), while Wnt-off survival 
seems to be mediated by all three tyrosine residues (Figure 11). Additionally, the 
critical role played by Y731 is also relevant in the regulation of tumor formation and 
proliferation as shown by Figure 12. These findings demonstrate tyrosine residue 731 
is a critical determinant in not only CRC cell survival but also has a detrimental effect 
on the cell's ability to proliferate and metastasize. Further work will be required to 
determine the relevance of this finding in CRC cells that have already metastasized 
from their point of origin and their respective levels of c-Cbl phosphorylation. 
 We investigated a c-Cbl target gene, EGFR, to determine whether c-Cbl mediates 
its effect on Wnt signaling and consequently CRC cell viability through EGFR 
expression. EGFR expression in DLD-1 cell lines (Wnt-on, Figure 13) exhibited 
results inconsistent with cell survival data (Figure 9), as EGFR expression seemed to 
be enhanced by WT c-Cbl expression. Elevated EGFR expression in Wnt-off cell line 
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(RKO, Figure 13) partially explains the increase in cell survival observed in WT c-
Cbl cells (Figure 11), however it does not necessarily explain the unchanged cell 
survival demonstrated by the phospho-mutants (Figure 11). This data suggests that a 
more intricate regulatory role is played by c-Cbl than previously thought, and further 
work is required to determine potential c-Cbl mediators in CRC cell survival.  
A potential expansion study investigating in detail more than two CRC cell lines 
to better understand the differential phosphorylation pattern exhibited by c-Cbl is 
warranted. Future plans also include expanding the trials to incorporate primary 
human CRC tumors. The MTT assay results were carried out in adherent 96 well 
plates, however recent literature in cancer biology45 has highlighted the greater 
relevance of using non-adherent plates, in order to accurately simulate tumor 
conditions. We plan to validate our findings using non-adherent plates, in order to 
expand their relevance to the human CRC condition. Although we investigated one 
potential mediator of c-Cbl regulation (EGFR), c-Cbl has an immense array of 
targets, which will require to be investigated in greater detail, through the use of 
genetic silencing or chemical inhibition. All the above data depict cell models and 
biochemical findings that ultimately require further validation in animal studies.    
The dichotomy presented here in the regulatory effect of c-Cbl on CRC survival 
and proliferation, can be potentially explored as a novel therapeutic target in mutant 
CRC tumors, which represent the majority of CRC cases in humans46. 
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